Watch out, Bristol Myers — J&J is right behind you; Blake Byers leaps out from GV to do his own thing
We’ve learned that J&J has now finished its rolling application for the BCMA-targeted cilta-cel, which one analyst believes will put them about 8 or 9 months behind Bristol Myers Squibb and their partners at bluebird, which just won a delayed OK at the FDA for ide-cel.
Legend included word of the wrap-up during Q1 in its 20F filing with the FDA, and analysts were quick to conclude that should allow for an approval by the end of this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.